Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.
Jorge Cortes, MD on OPTIC Trial #ASCO2020 #ASCO
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.